EZH2-Mediated Downregulation of the Tumor Suppressor DAB2IP Maintains Ovarian Cancer Stem Cells.

Abstract

The majority of women diagnosed with epithelial ovarian cancer eventually develop recurrence, which rapidly evolves into chemoresistant disease. Persistence of ovarian cancer stem cells (OCSC) at the end of therapy may be responsible for emergence of resistant tumors. In this study, we demonstrate that in OCSC, the tumor suppressor disabled homolog 2-interacting protein (DAB2IP) is silenced by EZH2-mediated H3K27 trimethylation of the DAB2IP promoter. CRISPR/Cas9-mediated deletion of DAB2IP in epithelial ovarian cancer cell lines upregulated expression of stemness-related genes and induced conversion of non-CSC to CSC, while enforced expression of DAB2IP suppressed CSC properties. Transcriptomic analysis showed that overexpression of DAB2IP in ovarian cancer significantly altered stemness-associated genes and bioinformatic analysis revealed WNT signaling as a dominant pathway mediating the CSC inhibitory effect of DAB2IP. Specifically, DAB2IP inhibited WNT signaling via downregulation of WNT5B, an important stemness inducer. Reverse phase protein array further demonstrated activation of noncanonical WNT signaling via C-JUN as a downstream target of WNT5B, which was blocked by inhibiting RAC1, a prominent regulator of C-JUN activation. Coadministration of EZH2 inhibitor GSK126 and RAC1 inhibitor NSC23766 suppressed OCSC survival in vitro and inhibited tumor growth and increased platinum sensitivity in vivo. Overall, these data establish that DAB2IP suppresses the cancer stem cell phenotype via inhibition of WNT5B-induced activation of C-JUN and can be epigenetically silenced by EZH2 in OCSC. Targeting the EZH2/DAB2IP/C-JUN axis therefore presents a promising strategy to prevent ovarian cancer recurrence and has potential for clinical translation. SIGNIFICANCE: These findings show that combining an epigenetic therapy with a noncanonical WNT signaling pathway inhibitor has the potential to eradicate ovarian cancer stem cells and to prevent ovarian cancer recurrence.

• Authors: Xingyue Zong, Weini Wang, Ali Ozes, Fang Fang, George E Sandusky, Kenneth P Nephew
• Journal: Cancer research (Cancer Res) Vol. 80 Issue 20 Pg. 4371-4385 (10 15 2020) ISSN: 1538-7445 [Electronic] United States
• PMID: 32816909 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
• Copyright: ©2020 American Association for Cancer Research.

Chemical References

• Aminoquinolines
• DAB2IP protein, human
• GSK-2816126
• Indoles
• NSC 23766
• Pyridones
• Pyrimidines
• RAC1 protein, human
• WNT5B protein, human
• Wnt Proteins
• ras GTPase-Activating Proteins
• EZH2 protein, human
• Enhancer of Zeste Homolog 2 Protein
• rac1 GTP-Binding Protein

Topics

• Aminoquinolines (pharmacology)
• Animals
• Cell Line, Tumor
• Down-Regulation
• Enhancer of Zeste Homolog 2 Protein (antagonists & inhibitors, genetics, metabolism)
• Epigenesis, Genetic
• Female
• Gene Expression Regulation, Neoplastic
• Genes, Tumor Suppressor
• Humans
• Indoles (pharmacology)
• Mice, SCID
• Neoplastic Stem Cells (pathology)
• Ovarian Neoplasms (drug therapy, genetics, mortality, pathology)
• Pyridones (pharmacology)
• Pyrimidines (pharmacology)
• Spheroids, Cellular (pathology)
• Wnt Proteins (antagonists & inhibitors, genetics, metabolism)
• Xenograft Model Antitumor Assays
• rac1 GTP-Binding Protein (metabolism)
• ras GTPase-Activating Proteins (genetics, metabolism)